These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 28491265)
1. Experience with ruxolitinib in the treatment of polycythaemia vera. Alimam S; Harrison C Ther Adv Hematol; 2017 Apr; 8(4):139-151. PubMed ID: 28491265 [TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039 [TBL] [Abstract][Full Text] [Related]
3. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. Greenfield G; McPherson S; Mills K; McMullin MF J Transl Med; 2018 Dec; 16(1):360. PubMed ID: 30558676 [TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Passamonti F; Griesshammer M; Palandri F; Egyed M; Benevolo G; Devos T; Callum J; Vannucchi AM; Sivgin S; Bensasson C; Khan M; Mounedji N; Saydam G Lancet Oncol; 2017 Jan; 18(1):88-99. PubMed ID: 27916398 [TBL] [Abstract][Full Text] [Related]
5. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. Reiter A; Harrison C Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383 [TBL] [Abstract][Full Text] [Related]
6. Management of polycythaemia vera: a critical review of current data. McMullin MF; Wilkins BS; Harrison CN Br J Haematol; 2016 Feb; 172(3):337-49. PubMed ID: 26492433 [TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib: a targeted treatment option for patients with polycythemia vera. Vaddi K; Verstovsek S; Kiladjian JJ Blood Lymphat Cancer; 2016; 6():7-19. PubMed ID: 31360077 [TBL] [Abstract][Full Text] [Related]
8. Recommendations for the diagnosis and treatment of patients with polycythaemia vera. Hatalova A; Schwarz J; Gotic M; Penka M; Hrubisko M; Kusec R; Egyed M; Griesshammer M; Podolak-Dawidziak M; Hellmann A; Klymenko S; Niculescu-Mizil E; Petrides PE; Grosicki S; Sever M; Cantoni N; Thiele J; Wolf D; Gisslinger H Eur J Haematol; 2018 Jul; ():. PubMed ID: 30058088 [TBL] [Abstract][Full Text] [Related]
10. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Bryan JC; Verstovsek S Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614 [TBL] [Abstract][Full Text] [Related]
11. ruxolitinib (JAKAVI°) and polycythaemia vera Inconclusive evaluation. Prescrire Int; 2016 Oct; 25(175):229-231. PubMed ID: 30645821 [TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Passamonti F; Palandri F; Saydam G; Callum J; Devos T; Guglielmelli P; Vannucchi AM; Zor E; Zuurman M; Gilotti G; Zhang Y; Griesshammer M Lancet Haematol; 2022 Jul; 9(7):e480-e492. PubMed ID: 35597252 [TBL] [Abstract][Full Text] [Related]
13. The advantages and risks of ruxolitinib for the treatment of polycythemia vera. Colafigli G; Scalzulli E; Pepe S; Di Prima A; Efficace F; Martelli M; Foà R; Breccia M Expert Rev Hematol; 2020 Oct; 13(10):1067-1072. PubMed ID: 32873088 [TBL] [Abstract][Full Text] [Related]
14. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? Nazha A; Gerds AT Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864 [TBL] [Abstract][Full Text] [Related]
15. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Bellucci S; Michiels JJ Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614 [TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851 [TBL] [Abstract][Full Text] [Related]